Supernus Pharmaceuticals (NASDAQ:SUPN) VP Padmanabh Bhatt Sells 50,000 Shares of Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh Bhatt sold 50,000 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $50.28, for a total transaction of $2,514,000.00. Following the transaction, the vice president owned 17,044 shares of the company’s stock, valued at approximately $856,972.32. The trade was a 74.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $49.29 on Thursday. The firm has a market cap of $2.84 billion, a price-to-earnings ratio of -72.48, a P/E/G ratio of 1.58 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $59.68. The firm’s 50-day simple moving average is $51.22 and its two-hundred day simple moving average is $49.17.

Institutional Trading of Supernus Pharmaceuticals

A number of institutional investors have recently modified their holdings of SUPN. Sit Investment Associates Inc. grew its position in shares of Supernus Pharmaceuticals by 0.4% in the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after purchasing an additional 250 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Supernus Pharmaceuticals by 30.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 268 shares during the period. Arizona State Retirement System lifted its holdings in Supernus Pharmaceuticals by 1.7% during the 3rd quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company’s stock worth $791,000 after purchasing an additional 277 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 281 shares in the last quarter. Finally, Maryland State Retirement & Pension System boosted its stake in Supernus Pharmaceuticals by 3.6% in the 4th quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock worth $415,000 after purchasing an additional 290 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday, March 8th. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Stifel Nicolaus boosted their target price on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Finally, Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.